We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
- Authors
Richardson, Paul G; Weller, Edie; Jagannath, Sundar; Avigan, David E; Alsina, Melissa; Schlossman, Robert L; Mazumder, Amitabha; Munshi, Nikhil C; Ghobrial, Irene M; Doss, Deborah; Warren, Diane L; Lunde, Laura E; McKenney, Mary; Delaney, Carol; Mitsiades, Constantine S; Hideshima, Teru; Dalton, William; Knight, Robert; Esseltine, Dixie-Lee; Anderson, Kenneth C
- Abstract
Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to bortezomib and dexamethasone. This phase I, dose-escalation study (ie, NCT00153933) evaluated safety and determined the maximum-tolerated dose (MTD) of lenalidomide plus bortezomib in patients with relapsed or with relapsed and refractory MM.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 34, p5713
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.22.2679